• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 15, 2024 at 12:02: PM
via
  • Preclinical data published in the Journal of Lipid Researchindicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys.
  • A Phase 1 trial of VXX-401 is ongoing, with topline results expected mid-2024.

article source
 

<



Similar threads

cafead
Vaxxinity Alzheimer’s treatment shows promising results in early trial
Replies
0
Views
82
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Vaxxinity celebrates trial success in early Parkinson’s therapy
Replies
0
Views
122
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Help wanted: Vaxxinity seeks a partner to press ahead with Alzheimer&#039;s treatment
Replies
0
Views
100
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Vaxxinity’s Phase III Covid-19 booster trial meets endpoints
Replies
0
Views
447
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Vaxxinity concludes subject enrolment in Phase III Covid-19 vaccine trial
Replies
0
Views
396
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote